| 5.99 -0.68 (-10.19%) | 12-05 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 8.99 | 1-year : | 10.51 |
| Resists | First : | 7.7 | Second : | 9 |
| Pivot price | 6.66 |
|||
| Supports | First : | 5.59 | Second : | 4.65 |
| MAs | MA(5) : | 6.28 |
MA(20) : | 6.9 |
| MA(100) : | 7.19 |
MA(250) : | 0 | |
| MACD | MACD : | -0.4 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 34.9 |
D(3) : | 32  |
| RSI | RSI(14): 41.9 |
|||
| 52-week | High : | 11.97 | Low : | 1.84 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TAOX ] has closed above bottom band by 17.3%. Bollinger Bands are 35.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.68 - 6.72 | 6.72 - 6.74 |
| Low: | 5.83 - 5.86 | 5.86 - 5.89 |
| Close: | 5.94 - 5.99 | 5.99 - 6.03 |
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
Tue, 18 Nov 2025
TAO Synergies (Nasdaq: TAOX) and Yuma host X livestream on Bittensor TAO halving, $750K fund - Stock Titan
Fri, 14 Nov 2025
TAO Synergies Bets Big On Decentralized AI Token Gains - Finimize
Tue, 04 Nov 2025
TAO Synergies makes its initial investment of $750,000 in Yuma Asset Management's Bittensor subsidiary fund. - Bitget
Tue, 04 Nov 2025
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds - Yahoo Finance
Mon, 20 Oct 2025
54,058 TAO Tokens — TAO Synergies Becomes Largest Publicly Traded Holder of Bittensor - Stock Titan
Mon, 20 Oct 2025
TAO Synergies stock soars after increasing Bittensor token holdings - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 182 (K) |
| Shares Short P.Month | 847 (K) |
| EPS | -14.2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.54 |
| Profit Margin | 0 % |
| Operating Margin | -884.9 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -178.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.02 |
| Sales Per Share | 0.02 |
| EBITDA (p.s.) | -1.04 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -5 (M) |
| Levered Free Cash Flow | -19 (M) |
| PE Ratio | -0.43 |
| PEG Ratio | 0 |
| Price to Book value | 1.68 |
| Price to Sales | 205.99 |
| Price to Cash Flow | -8.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|